Korro Bio, an RNA editing company focused on the discovery and development of novel genetic medicines, entered into an agreement with Genevant Sciences, a nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, to combine Korro’s RNA editing platform with Genevant’s LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD). Terms of the agreement were not disclose...